Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 14:8:678.
doi: 10.3389/fonc.2018.00678. eCollection 2018.

Is Proton Therapy a "Pro" for Breast Cancer? A Comparison of Proton vs. Non-proton Radiotherapy Using the National Cancer Database

Mudit Chowdhary  1 , Anna Lee  2 , Sarah Gao  3 , Dian Wang  1 , Parul N Barry  1 , Roberto Diaz  4 , Neeti R Bagadiya  5 , Henry S Park  3 , James B Yu  3 , Lynn D Wilson  3 , Meena S Moran  3 , Susan A Higgins  3 , Christin A Knowlton  3 , Kirtesh R Patel  3
Affiliations

Is Proton Therapy a "Pro" for Breast Cancer? A Comparison of Proton vs. Non-proton Radiotherapy Using the National Cancer Database

Mudit Chowdhary et al. Front Oncol. .

Abstract

Background: Limited data exists demonstrating the clinical benefit of proton radiotherapy (PRT) in breast cancer. Using the National Cancer Database, we evaluated predictors associated with PRT use for patients with breast cancer. An exploratory analysis also investigates the impact of PRT on overall survival (OS). Methods: Patients with non-metastatic breast cancer treated with adjuvant radiotherapy from 2004 to 2014 were identified. Patients were stratified based on receipt of PRT or non-PRT (i.e., photons ± electrons). A logistic regression model was used to determine predictors for PRT utilization. For OS, Multivariable analysis (MVA) was performed using Cox proportional hazard model. Results: A total of 724,492 patients were identified: 871 received PRT and 723,621 received non-PRT. 58.3% of the PRT patients were group stage 0-1. Median follow-up time was 62.2 months. On multivariate logistic analysis, the following factors were found to be significant for receipt of PRT (all p < 0.05): academic facility (odds ratio [OR] = 2.50), South (OR = 2.01) and West location (OR = 12.43), left-sided (OR = 1.21), ER-positive (OR = 1.59), and mastectomy (OR = 1.47); pT2-T4 disease predicted for decrease use (OR = 0.79). PRT was not associated with OS on MVA for all patients: Hazard Ratio: 0.85, p = 0.168. PRT remained not significant on MVA after stratifying for subsets likely associated with higher heart radiation doses, including: left-sided (p = 0.140), inner-quadrant (p = 0.173), mastectomy (p = 0.095), node positivity (p = 0.680), N2-N3 disease (p = 0.880), and lymph node irradiation (LNI) (p = 0.767). Conclusions: Receipt of PRT was associated with left-sided, ER+ tumors, mastectomy, South and West location, and academic facilities, but not higher group stages or LNI. PRT was not associated with OS, including in subsets likely at risk for higher heart doses. Further studies are required to determine non-OS benefits of PRT. In the interim, given the high cost of protons, only well-selected patients should receive PRT unless enrolled on a clinical trial.

Keywords: breast cancer; overall survival; patterns of care; proton; radiotherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Consort Diagram for selection of patient cohort.
Figure 2
Figure 2
Kaplan-Meier survival analysis of breast cancer patients receiving adjuvant proton and non-proton radiotherapy.
See this image and copyright information in PMC

References

    1. Early Breast Cancer Trialists' Collaborative Group. Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. . Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet (2011) 378:1707–16. 10.1016/S0140-6736(11)61629-2 - DOI - PMC - PubMed
    1. Darby SC, Ewertz M, McGale P, Bennet AM, Goldman UB, Brønnum D, et al. . Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. (2013) 368:987–98. 10.1056/NEJMoa1209825 - DOI - PubMed
    1. Moran MS. Advancements and personalization of breast cancer treatment strategies in radiation therapy. Cancer Treat Res. (2018) 173:89–119. 10.1007/978-3-319-70197-4_7 - DOI - PubMed
    1. Thorsen LB, Offersen BV, Dano H, Berg M, Jensen I, Pedersen AN, et al. . DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. J Clin Oncol. (2016) 34:314–20. 10.1200/JCO.2015.63.6456 - DOI - PubMed
    1. Levin WP, Kooy H, Loeffler JS, DeLaney TF. Proton beam therapy. Br J Cancer (2005) 93:849–54. 10.1038/sj.bjc.6602754 - DOI - PMC - PubMed

LinkOut - more resources